Skip to main content
SpringerLink
Log in

Hepatozelluläres Karzinom

Wann ist eine TACE, wann Sorafenib indiziert?

  • panorama
  • Published:
best practice onkologie Aims and scope

Bei Patienten mit hepatozellulärem Karzinom (HCC) im intermediären BCLC (Barcelona Clinic Liver Cancer Staging System)-Stadium B gilt die transarterielle Chemoembolisation (TACE) als Standard.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Symposium der Bayer Vital GmbH

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    arn

Authors
  1. arn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

arn Wann ist eine TACE, wann Sorafenib indiziert?. best practice onkologie 9, 13 (2014). https://doi.org/10.1007/s11654-014-0545-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-014-0545-7

Search

Navigation